Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
← catalyst calendarSponsored by Revolution Medicines, Inc. (industry) · RVMD — their whole pipeline →.
Phase
—
Status
Approved for marketing
Study type
Expanded access
Sites
257
Countries
Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-09-01
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | — | When the study began enrolling | |
| Primary completion | — | The date the last participant is measured for the primary outcome — the readout window | |
| Study completion | — | The whole study's end, after follow-up | |
| First posted | 2026-05-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-09-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
- Metastatic Pancreas Adenocarcinoma
- Pancreatic Cancer
- Pancreatic Cancer Metastatic
- Pancreatic Adenocarcinoma Metastatic
- Pancreatic Adenocarcinoma
- Pancreatic Adenosquamous Carcinoma
Intervention
- Drug: daraxonrasib — also filed as RMC-6236, RMC-0706236
Related
RVMD · their whole pipeline · Pancreatic Cancer readouts · Executive-branch trades in RVMD
RVMD's other studiesmost recently updated first
- Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) Phase 3 · Recruiting
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Phase 3 · Recruiting
- Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) Phase 3 · Recruiting
- Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) Phase 3 · Recruiting
- Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC Phase 3 · Recruiting
Permalink · RVMD's whole pipeline · Catalyst calendar · Every registered study · What changed